NOBO Medicine, Inc. leverages NOBO-VERSE clinical database to identify patients most likely to respond favorably to new targeted therapies, thereby enhancing the efficiency and success rates of drug development. Leveraging this cutting-edge technology, we are committed to addressing unmet medical needs in cancer and chronic diseases.
| Project | Indication | Discovery | Preclinical | Phase Ⅰ | Phase Ⅱ | Phase Ⅲ | Approved |
|---|---|---|---|---|---|---|---|
| Project 201 Poseltinib |
R/R DLBCL |
|
|||||
| Project 202 Poseltinib |
R/R PCNSL |
|
|||||
| Project 101 Emricasan |
CVD |
|
|||||
| Project 102 Emricasan |
AMD |
|
|||||
| Project 301 Selective Caspase inhibitor |
Inflammatory |
|
|||||
| Project 401 PPM1D inhibitor |
Oncology |
|
|||||
| Project 501 Undisclosed |
Oncology |
|
|||||